iMDx Announces $26.0 Million Registered Direct Offering
Insight Molecular Diagnostics Inc. (IMDX)
Company Research
Source: GlobeNewswire
NASHVILLE, Tenn., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (“iMDx” or the “Company”), today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of an aggregate of 4,525,976 shares of its common stock, no par value per share (or pre-funded warrants in lieu thereof) at an offering price of $5.75 per share in a registered direct offering. The purchase price per pre-funded warrant is identical to the purchase price per share of common stock, less the exercise price of $0.0001 per share. The offering is expected to close on February 12, 2026, subject to the satisfaction of customary closing conditions. Lake Street Capital Markets, LLC is acting as the sole placement agent for the offering. The aggregate gross proceeds to the Company from the offering are expected to be approximately $26.0 million, before deducting the placement agent’s fees and other offering expenses payabl
Show less
Read more
Impact Snapshot
Event Time:
IMDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMDX alerts
High impacting Insight Molecular Diagnostics Inc. news events
Weekly update
A roundup of the hottest topics
IMDX
News
- Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission [Yahoo! Finance]Yahoo! Finance
- Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA SubmissionGlobeNewswire
- How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And GraftAssureDx Catalyst [Yahoo! Finance]Yahoo! Finance
- Oncocyte (NASDAQ:IMDX) had its price target raised by analysts at Lake Street Capital from $8.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Insight ‘congratulated' STAR working group on organ health testing paper [Yahoo! Finance]Yahoo! Finance
IMDX
Sec Filings
- 2/26/26 - Form 8-K
- 2/12/26 - Form SCHEDULE
- 2/12/26 - Form 4
- IMDX's page on the SEC website